Absence of system xc- in mice decreases anxiety and depressive-like behavior without affecting sensorimotor function or spatial vision

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 59, Issue , 2015, Pages 49-58

  Bentea, Eduard ^a   Demuyser, Thomas ^a   Van Liefferinge, Joeri ^a   Albertini, Giulia ^a   Deneyer, Lauren ^a   Nys, Julie ^b   Merckx, Ellen ^a   Michotte, Yvette ^a   Sato, Hideyo ^c   Arckens, Lutgarde ^b   Massie, Ann ^a   Smolders, Ilse ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c NIIGATA UNIVERSITY   (Japan)

Author keywords

Anxiety; Depression; Sensorimotor; System xc ; Vision; XCT

Indexed keywords

ANTIPORTER; GLIAL CYSTINE GLUTAMATE ANTIPORTER; GLUTAMIC ACID; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; SLC7A11 PROTEIN, MOUSE;

ADHESIVE REMOVAL TEST; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BRAIN FUNCTION; BRAIN REGION; CONTROLLED STUDY; DEPRESSION; ELEVATED PLUS MAZE TEST; FEMALE; FORCED SWIM TEST; MALE; MOOD DISORDER; MOTOR PERFORMANCE; MOUSE; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; OPEN FIELD TEST; PHENOTYPE; ROTAROD TEST; SENSORIMOTOR FUNCTION; SIGNAL TRANSDUCTION; SPATIAL VISION; TAIL SUSPENSION TEST; VISION; VISUAL ACUITY; AGING; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; DEFICIENCY; DEPTH PERCEPTION; EXPLORATORY BEHAVIOR; FEEDING BEHAVIOR; GENETICS; GENOTYPE; MAZE TEST; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE; SWIMMING; TIME; TRANSGENIC MOUSE; VISUAL ADAPTATION;

ADAPTATION, OCULAR; AGING; AMINO ACID TRANSPORT SYSTEM Y+; ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; DEPRESSION; EXPLORATORY BEHAVIOR; FEEDING BEHAVIOR; GENOTYPE; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; PSYCHOMOTOR PERFORMANCE; SPACE PERCEPTION; SWIMMING; TIME FACTORS; VISUAL ACUITY;

EID: 84922031968     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.01.010     Document Type: Article

References (76)

1. Bai F., Li X., Clay M., Lindstrom T., Skolnick P. Intra- and interstrain differences in models of "behavioral despair". Pharmacol Biochem Behav 2001, 70:187-192.
2. Baker D.A., Xi Z.X., Shen H., Swanson C.J., Kalivas P.W. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 2002, 22:9134-9141.
3. Baker D.A., McFarland K., Lake R.W., Shen H., Tang X.C., Toda S., et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 2003, 6:743-749.
4. Bergink V., van Megen H.J., Westenberg H.G. Glutamate and anxiety. Eur Neuropsychopharmacol 2004, 14:175-183.
5. Bouet V., Boulouard M., Toutain J., Divoux D., Bernaudin M., Schumann-Bard P., et al. The adhesive removal test: a sensitive method to assess sensorimotor deficits in mice. Nat Protoc 2009, 4:1560-1564.
6. Bridges C.C., Kekuda R., Wang H., Prasad P.D., Mehta P., Huang W., et al. Structure, function, and regulation of human cystine/glutamate transporter in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2001, 42:47-54.
7. Bridges R., Lutgen V., Lobner D., Baker D.A. Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling. Pharmacol Rev 2012, 64:780-802.
8. Browne C.A., Lucki I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 2013, 4:161.
9. Burdo J., Dargusch R., Schubert D. Distribution of the cystine/glutamate antiporter system xc- in the brain, kidney, and duodenum. J Histochem Cytochem 2006, 54:549-557.
10. Button K.S., Ioannidis J.P., Mokrysz C., Nosek B.A., Flint J., Robinson E.S., et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 2013, 14:365-376.
11. Byrne G.J., Pachana N.A. Anxiety and depression in the elderly: do we know any more?. Curr Opin Psychiatry 2010, 23:504-509.
12. Chaudhuri K.R., Schapira A.H. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8:464-474.
13. Crabbe J.C., Wahlsten D., Dudek B.C. Genetics of mouse behavior: interactions with laboratory environment. Science 1999, 284:1670-1672.
14. Crawley J.N. Behavioral phenotyping strategies for mutant mice. Neuron 2008, 57:809-818.
15. Crawley J.N., Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav 1997, 31:197-211.
16. Cryan J.F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005, 4:775-790.
17. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002, 23:238-245.
18. Danbolt N.C. Glutamate uptake. Prog Neurobiol 2001, 65:1-105.
19. De Bundel D., Schallier A., Loyens E., Fernando R., Miyashita H., Van Liefferinge J., et al. Loss of system x(c)- does not induce oxidative stress but decreases extracellular glutamate in hippocampus and influences spatial working memory and limbic seizure susceptibility. J Neurosci 2011, 31:5792-5803.
20. Deacon R.M. Assessing nest building in mice. Nat Protoc 2006, 1:1117-1119.
21. Douglas R.M., Alam N.M., Silver B.D., McGill T.J., Tschetter W.W., Prusky G.T. Independent visual threshold measurements in the two eyes of freely moving rats and mice using a virtual-reality optokinetic system. Vis Neurosci 2005, 22:677-684.
22. Dulawa S.C., Holick K.A., Gundersen B., Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004, 29:1321-1330.
23. Dun Y., Mysona B., Van Ells T., Amarnath L., Ola M.S., Ganapathy V., et al. Expression of the cystine-glutamate exchanger (xc-) in retinal ganglion cells and regulation by nitric oxide and oxidative stress. Cell Tissue Res 2006, 324:189-202.
24. Flint A.J. Anxiety and its disorders in late life: moving the field forward. Am J Geriatr Psychiatry 2005, 13:3-6.
25. Fonio E., Benjamini Y., Golani I. Short and long term measures of anxiety exhibit opposite results. PLoS One 2012, 7:e48414.
26. Gomez-Galan M., De Bundel D., Van Eeckhaut A., Smolders I., Lindskog M. Dysfunctional astrocytic regulation of glutamate transmission in a rat model of depression. Mol Psychiatry 2013, 18:582-594.
27. Griebel G., Holmes A. 50years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 2013, 12:667-687.
28. Hu R.G., Lim J., Donaldson P.J., Kalloniatis M. Characterization of the cystine/glutamate transporter in the outer plexiform layer of the vertebrate retina. Eur J Neurosci 2008, 28:1491-1502.
29. Inta D., Vogt M.A., Luoni A., Filipovic D., Lima-Ojeda J.M., Pfeiffer N., et al. Significant increase in anxiety during aging in mGlu5 receptor knockout mice. Behav Brain Res 2013, 241:27-31.
30. Kato S., Ishita S., Sugawara K., Mawatari K. Cystine/glutamate antiporter expression in retinal Muller glial cells: implications for DL-alpha-aminoadipate toxicity. Neuroscience 1993, 57:473-482.
31. Laks J., Engelhardt E. Peculiarities of geriatric psychiatry: a focus on aging and depression. CNS Neurosci Ther 2010, 16:374-379.
32. Langford M.P., Redmond P., Chanis R., Misra R.P., Redens T.B. Glutamate, excitatory amino acid transporters, xc- antiporter, glutamine synthetase, and gamma-glutamyltranspeptidase in human corneal epithelium. Curr Eye Res 2010, 35:202-211.
33. Lehmann K., Schmidt K.F., Lowel S. Vision and visual plasticity in ageing mice. Restor Neurol Neurosci 2012, 30:161-178.
34. Lewerenz J., Hewett S.J., Huang Y., Lambros M., Gout P.W., Kalivas P.W., et al. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal 2013, 18:522-555.
35. Li X., Frye M.A., Shelton R.C. Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology 2012, 37:77-101.
36. Lim J.C., Donaldson P.J. Focus on molecules: the cystine/glutamate exchanger (System x(c)(-)). Exp Eye Res 2011, 92:162-163.
37. Lim J., Lam Y.C., Kistler J., Donaldson P.J. Molecular characterization of the cystine/glutamate exchanger and the excitatory amino acid transporters in the rat lens. Invest Ophthalmol Vis Sci 2005, 46:2869-2877.
38. Liu X., Ding X., Deshmukh G., Liederer B.M., Hop C.E. Use of the cassette-dosing approach to assess brain penetration in drug discovery. Drug Metab Dispos 2012, 40:963-969.
39. Lutgen V., Resch J., Qualmann K., Raddatz N.J., Panhans C., Olander E.M., et al. Behavioral assessment of acute inhibition of system xc (-) in rats. Psychopharmacology (Berl) 2014, 231:4637-4647.
40. Massie A., Schallier A., Kim S.W., Fernando R., Kobayashi S., Beck H., et al. Dopaminergic neurons of system x(c)(-)-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity. FASEB J 2011, 25:1359-1369.
41. McCullagh E.A., Featherstone D.E. Behavioral characterization of system xc- mutant mice. Behav Brain Res 2014, 265:1-11.
42. Miller C.C., Holmes P.V., Edwards G.L. Area postrema lesions elevate NPY levels and decrease anxiety-related behavior in rats. Physiol Behav 2002, 77:135-140.
43. Mineur Y.S., Picciotto M.R., Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry 2007, 61:250-252.
44. Moran M.M., McFarland K., Melendez R.I., Kalivas P.W., Seamans J.K. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 2005, 25:6389-6393.
45. Mysona B., Dun Y., Duplantier J., Ganapathy V., Smith S.B. Effects of hyperglycemia and oxidative stress on the glutamate transporters GLAST and system xc- in mouse retinal Muller glial cells. Cell Tissue Res 2009, 335:477-488.
46. Niciu M.J., Ionescu D.F., Richards E.M., Zarate C.A. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm 2014, 121:907-924.
47. Patel N., Jankovic J., Hallett M. Sensory aspects of movement disorders. Lancet Neurol 2014, 13:100-112.
48. Pietropaolo S., Feldon J., Yee B.K. Environmental enrichment eliminates the anxiety phenotypes in a triple transgenic mouse model of Alzheimer's disease. Cogn Affect Behav Neurosci 2014, 14:996-1008.
49. Pilc A., Wieronska J.M., Skolnick P. Glutamate-based antidepressants: preclinical psychopharmacology. Biol Psychiatry 2013, 73:1125-1132.
50. Pogorelov V.M., Lanthorn T.H., Savelieva K.V. Use of a platform in an automated open-field to enhance assessment of anxiety-like behaviors in mice. J Neurosci Methods 2007, 162:222-228.
51. Popoli M., Yan Z., McEwen B.S., Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 2012, 13:22-37.
52. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
53. Proville R.D., Spolidoro M., Guyon N., Dugue G.P., Selimi F., Isope P., et al. Cerebellum involvement in cortical sensorimotor circuits for the control of voluntary movements. Nat Neurosci 2014, 17:1233-1239.
54. Prusky G.T., Alam N.M., Beekman S., Douglas R.M. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest Ophthalmol Vis Sci 2004, 45:4611-4616.
55. Ramos A. Animal models of anxiety: do I need multiple tests?. Trends Pharmacol Sci 2008, 29:493-498.
56. Rodgers R.J., Cole J.C., Aboualfa K., Stephenson L.H. Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze. Pharmacol Biochem Behav 1995, 52:805-813.
57. Ryu B.R., Lee Y.A., Won S.J., Noh J.H., Chang S.Y., Chung J.M., et al. The novel neuroprotective action of sulfasalazine through blockade of NMDA receptors. J Pharmacol Exp Ther 2003, 305:48-56.
58. Sanacora G., Banasr M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol Psychiatry 2013, 73:1172-1179.
59. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008, 7:426-437.
60. Sato H., Tamba M., Okuno S., Sato K., Keino-Masu K., Masu M., et al. Distribution of cystine/glutamate exchange transporter, system x(c)-, in the mouse brain. J Neurosci 2002, 22:8028-8033.
61. Sato H., Shiiya A., Kimata M., Maebara K., Tamba M., Sakakura Y., et al. Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol Chem 2005, 280:37423-37429.
62. Shih A.Y., Erb H., Sun X., Toda S., Kalivas P.W., Murphy T.H. Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation. J Neurosci 2006, 26:10514-10523.
63. Slotkin T.A., Miller D.B., Fumagalli F., McCook E.C., Zhang J., Bissette G., et al. Modeling geriatric depression in animals: biochemical and behavioral effects of olfactory bulbectomy in young versus aged rats. J Pharmacol Exp Ther 1999, 289:334-345.
64. Smith G.S., Gunning-Dixon F.M., Lotrich F.E., Taylor W.D., Evans J.D. Translational research in late-life mood disorders: implications for future intervention and prevention research. Neuropsychopharmacology 2007, 32:1857-1875.
65. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370.
66. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005, 4:131-144.
67. Turri M.G., Datta S.R., DeFries J., Henderson N.D., Flint J. QTL analysis identifies multiple behavioral dimensions in ethological tests of anxiety in laboratory mice. Curr Biol 2001, 11:725-734.
68. Valentine G.W., Mason G.F., Gomez R., Fasula M., Watzl J., Pittman B., et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 2011, 191:122-127.
69. Viswanath H., Carter A.Q., Baldwin P.R., Molfese D.L., Salas R. The medial habenula: still neglected. Front Hum Neurosci 2013, 7:931.
70. Voikar V., Vasar E., Rauvala H. Behavioral alterations induced by repeated testing in C57BL/6J and 129S2/Sv mice: implications for phenotyping screens. Genes Brain Behav 2004, 3:27-38.
71. Wahl C., Liptay S., Adler G., Schmid R.M. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998, 101:1163-1174.
72. Wahlsten D., Rustay N.R., Metten P., Crabbe J.C. In search of a better mouse test. Trends Neurosci 2003, 26:132-136.
73. Young E., Korszun A. Sex, trauma, stress hormones and depression. Mol Psychiatry 2010, 15:23-28.
74. Zarate C., Machado-Vieira R., Henter I., Ibrahim L., Diazgranados N., Salvadore G. Glutamatergic modulators: the future of treating mood disorders?. Harv Rev Psychiatry 2010, 18:293-303.
75. Zarate C., Duman R.S., Liu G., Sartori S., Quiroz J., Murck H. New paradigms for treatment-resistant depression. Ann N Y Acad Sci 2013, 1292:21-31.
76. Zhu L., Wu L., Yu B., Liu X. The participation of a neurocircuit from the paraventricular thalamus to amygdala in the depressive like behavior. Neurosci Lett 2011, 488:81-86.